Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry
- PMID: 31863522
- DOI: 10.1002/ejhf.1645
Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry
Erratum in
-
Corrigendum to 'Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry' [Eur J Heart Fail 2020;22:92-102].Eur J Heart Fail. 2020 Jul;22(7):1287. doi: 10.1002/ejhf.1947. Eur J Heart Fail. 2020. PMID: 32945101 No abstract available.
Abstract
Aims: This study aimed to assess age- and sex-related differences in management and 1-year risk for all-cause mortality and hospitalization in chronic heart failure (HF) patients.
Methods and results: Of 16 354 patients included in the European Society of Cardiology Heart Failure Long-Term Registry, 9428 chronic HF patients were analysed [median age: 66 years; 28.5% women; mean left ventricular ejection fraction (LVEF) 37%]. Rates of use of guideline-directed medical therapy (GDMT) were high (angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers and mineralocorticoid receptor antagonists: 85.7%, 88.7% and 58.8%, respectively). Crude GDMT utilization rates were lower in women than in men (all differences: P ≤ 0.001), and GDMT use became lower with ageing in both sexes, at baseline and at 1-year follow-up. Sex was not an independent predictor of GDMT prescription; however, age >75 years was a significant predictor of GDMT underutilization. Rates of all-cause mortality were lower in women than in men (7.1% vs. 8.7%; P = 0.015), as were rates of all-cause hospitalization (21.9% vs. 27.3%; P < 0.001) and there were no differences in causes of death. All-cause mortality and all-cause hospitalization increased with greater age in both sexes. Sex was not an independent predictor of 1-year all-cause mortality (restricted to patients with LVEF ≤45%). Mortality risk was significantly lower in patients of younger age, compared to patients aged >75 years.
Conclusions: There was a decline in GDMT use with advanced age in both sexes. Sex was not an independent predictor of GDMT or adverse outcomes. However, age >75 years independently predicted lower GDMT use and higher all-cause mortality in patients with LVEF ≤45%.
Keywords: Age; Hospitalization; Mortality; Registry; Sex.
© 2019 The Authors. European Journal of Heart Failure © 2019 European Society of Cardiology.
Similar articles
-
Guideline-directed medical therapy implementation during hospitalization for cardiogenic shock.ESC Heart Fail. 2025 Feb;12(1):60-70. doi: 10.1002/ehf2.14863. Epub 2024 Sep 26. ESC Heart Fail. 2025. PMID: 39327768 Free PMC article.
-
Association between a hospitalization for heart failure and the initiation/discontinuation of guideline-recommended treatments: An analysis from the Swedish Heart Failure Registry.Eur J Heart Fail. 2023 Jul;25(7):1132-1144. doi: 10.1002/ejhf.2928. Epub 2023 Jun 27. Eur J Heart Fail. 2023. PMID: 37317585
-
Impact of adherence to guideline-directed therapy on risk of death in HF patients across an ejection fraction spectrum.ESC Heart Fail. 2023 Dec;10(6):3656-3666. doi: 10.1002/ehf2.14358. Epub 2023 Oct 6. ESC Heart Fail. 2023. PMID: 37803813 Free PMC article.
-
Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction.Eur J Heart Fail. 2021 Dec;23(12):1999-2007. doi: 10.1002/ejhf.2378. Epub 2021 Dec 13. Eur J Heart Fail. 2021. PMID: 34755422 Review.
-
Bridging gaps and optimizing implementation of guideline-directed medical therapy for heart failure.Prog Cardiovasc Dis. 2024 Jan-Feb;82:61-69. doi: 10.1016/j.pcad.2024.01.008. Epub 2024 Jan 18. Prog Cardiovasc Dis. 2024. PMID: 38244825 Review.
Cited by
-
Sex Differences in Cardiac and Clinical Phenotypes and Their Relation to Outcomes in Patients with Heart Failure.J Pers Med. 2024 Feb 12;14(2):201. doi: 10.3390/jpm14020201. J Pers Med. 2024. PMID: 38392634 Free PMC article. Review.
-
An Observational Study of Evidence-Based Therapies in Older Patients with Heart Failure with Reduced Ejection Fraction: Insights from a Dedicated Heart Failure Clinic.J Clin Med. 2024 Nov 26;13(23):7171. doi: 10.3390/jcm13237171. J Clin Med. 2024. PMID: 39685630 Free PMC article.
-
How to Manage Beta-Blockade in Older Heart Failure Patients: A Scoping Review.J Clin Med. 2024 Apr 5;13(7):2119. doi: 10.3390/jcm13072119. J Clin Med. 2024. PMID: 38610883 Free PMC article.
-
Heart failure treatment patterns: A pharmacoepidemiological descriptive study in Colombia (The HEATCO study).PLoS One. 2025 Jun 24;20(6):e0325515. doi: 10.1371/journal.pone.0325515. eCollection 2025. PLoS One. 2025. PMID: 40554586 Free PMC article.
-
Acute heart failure in elderly patients: a review of invasive and non-invasive management.J Geriatr Cardiol. 2021 Jul 28;18(7):560-576. doi: 10.11909/j.issn.1671-5411.2021.07.004. J Geriatr Cardiol. 2021. PMID: 34404992 Free PMC article.
References
-
- Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;386:743-800.
-
- Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jimenez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P. Heart Disease and Stroke Statistics 2017 Update: a report from the American Heart Association. Circulation 2017;135:e146-e603.
-
- Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Piepoli MF, Crespo-Leiro MG, Laroche C, Seferovic PM, Anker SD, Ferrari R, Ruschitzka F, Lopez-Fernandez S, Miani D, Filippatos G, Maggioni AP. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017;19:1242-1254.
-
- Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC, Shimokawa H, Budi Siswanto B, Sliwa K, Filippatos G. Heart failure: preventing disease and death worldwide. ESC Heart Fail 2014;1:4-25.
-
- Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, Ferrari R, Piepoli MF, Delgado Jimenez JF, Metra M, Fonseca C, Hradec J, Amir O, Logeart D, Dahlstrom U, Merkely B, Drozdz J, Goncalvesova E, Hassanein M, Chioncel O, Lainscak M, Seferovic PM, Tousoulis D, Kavoliuniene A, Fruhwald F, Fazlibegovic E, Temizhan A, Gatzov P, Erglis A, Laroche C, Mebazaa A. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail 2016;18:613-625.
Publication types
MeSH terms
Substances
Grants and funding
- Abbott Vascular International/International
- Amgen Cardiovascular/International
- AstraZeneca/International
- Bayer AG/International
- Boehringer Ingelheim/International
- Boston Scientific/International
- Bristol-Myers Squibb and Pfizer Alliance/International
- Daiichi Sankyo Europe GmbH/International
- Daiichi Sankyo Europe GmbH and Eli Lilly & Company Alliance/International
- Edwards/International
- Gedeon Richter/International
- Menarini International Operations/International
- MSD-Merck & Co/International
- Novartis Pharma AG/International
- ResMed/International
- Sanofi/International
- Servier/International
- Vifor/International
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous